[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
September 14, 2005

Localized Prostate Cancer and DNA Ploidy—Reply

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;294(10):1207-1208. doi:10.1001/jama.294.10.1207-b

In Reply: The extraordinary variability in prostate cancer clinical outcomes poses a significant challenge to anyone counseling patients about treatment for clinically localized disease. Clinicians have relied on stage and grade to quantify prognosis accurately. Gleason and Mellinger and members of the Veterans Administration Cooperative Urological Research Group developed a low-power scoring system that standardized prostate cancer readings worldwide.1 Unfortunately, as indicated by Dr Koss, the system is inherently subjective and therefore prone to differing interpretations. In its place, Dr Koss suggests an analysis of DNA content.

First Page Preview View Large
First page PDF preview
First page PDF preview
×